Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows

Simply Wall St.04-21 21:09

Vir Biotechnology announced that its global collaboration and licensing agreement with Astellas has closed, bringing in a US$240,000,000 upfront payment, a US$75,000,000 equity investment at US$10.36 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629058630?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-21 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629058630","market":"sg","top_or_hot":-1,"title":"Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows","media":"Simply Wall St.","content":"<div>\n<p>Vir Biotechnology announced that its global collaboration and licensing agreement with Astellas has closed, bringing in a US$240,000,000 upfront payment, a US$75,000,000 equity investment at US$10.36 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/vir-biotechnology-vir-is-up-191-after-astellas-cancer-pact-c\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-21 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/vir-biotechnology-vir-is-up-191-after-astellas-cancer-pact-c><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vir Biotechnology announced that its global collaboration and licensing agreement with Astellas has closed, bringing in a US$240,000,000 upfront payment, a US$75,000,000 equity investment at US$10.36 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/vir-biotechnology-vir-is-up-191-after-astellas-cancer-pact-c\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/vir-biotechnology-vir-is-up-191-after-astellas-cancer-pact-c","article_id":"2629058630","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/vir-biotechnology-vir-is-up-191-after-astellas-cancer-pact-c","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629058630","pubTimestamp":1776776962,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Vir Biotechnology announced that its global collaboration and licensing agreement with Astellas has closed, bringing in a US$240,000,000 upfront payment, a US$75,000,000 equity investment at US$10.36 per share, and near-term and potential milestone payments tied to the development and commercialization of VIR-5500 for metastatic prostate cancer.\nAt the same time, Vir has begun enrolling an expansion cohort in its Phase 1 trial of VIR-5500 following early safety and anti-tumor signals,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","BK4139":"生物科技","VIR":"Vir Biotechnology, Inc.","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念"},"translate_title":"安斯泰来癌症协议完成后，Vir Biotechnology(VIR)股价上涨19.1%，资金流入3.15亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":1.5},"content_text":"Vir Biotechnology announced that its global collaboration and licensing agreement with Astellas has closed, bringing in a US$240,000,000 upfront payment, a US$75,000,000 equity investment at US$10.36 per share, and near-term and potential milestone payments tied to the development and commercialization of VIR-5500 for metastatic prostate cancer. At the same time, Vir has begun enrolling an expansion cohort in its Phase 1 trial of VIR-5500 following early safety and anti-tumor signals, linking fresh clinical progress to a substantially strengthened funding and co-development base with Astellas. We’ll now examine how this Astellas partnership, especially the US profit-and-loss sharing on VIR-5500, could reshape Vir’s investment narrative. Uncover the next big thing with 26 elite penny stocks that balance risk and reward.AdvertisementVir Biotechnology Investment Narrative RecapTo own Vir Biotechnology, you have to believe its PRO XTEN T cell engager platform and hepatitis portfolio can eventually justify ongoing losses and heavy R&D spend. In the near term, clinical progress with VIR 5500 and clear funding visibility are key potential catalysts, while trial setbacks or further dilution remain central risks. The Astellas deal materially boosts Vir’s cash position and shares U.S. economics on VIR 5500, but it does not remove the underlying clinical and execution risk. The most relevant recent announcement is the closing of the Astellas collaboration, which locks in a US$240,000,000 upfront payment, a US$75,000,000 equity investment and a near term US$20,000,000 milestone. Tied directly to VIR 5500, this partnership both validates the program externally and provides shared U.S. profit and loss economics if it reaches market, while still leaving Vir exposed to trial, regulatory and commercialization risks across its broader pipeline. Yet investors should also weigh how continued net losses and the possibility of future capital raises could affect them if VIR 5500 or hepatitis programs do not... Read the full narrative on Vir Biotechnology (it's free!)Vir Biotechnology’s narrative projects $141.9 million revenue and $21.0 million earnings by 2029.Uncover how Vir Biotechnology's forecasts yield a $20.78 fair value, a 87% upside to its current price.Exploring Other PerspectivesVIR 1-Year Stock Price Chart Some of the most optimistic analysts were assuming revenue could reach about US$356 million by 2029, which is a far more aggressive view than the baseline story, and before this Astellas news they treated the PRO XTEN platform as a major swing factor, so you should recognize that opinions differ widely and may shift again as VIR 5500 data and partnership economics evolve.Explore 2 other fair value estimates on Vir Biotechnology - why the stock might be worth as much as 87% more than the current price!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Vir Biotechnology research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.Our free Vir Biotechnology research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vir Biotechnology's overall financial health at a glance.Curious About Other Options?Our daily scans reveal stocks with breakout potential. Don't miss this chance:Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629058630","isCrawlerRequest":true}